ÂÜÀòÂÒÂ×

Ross Rounsevell has held various roles in the biotechnology and healthcare industries since 2005. In 2005, they were a Postdoctoral Researcher at the University of Cambridge. From 2006 to 2017, they were a Postdoctoral Researcher at the University of California, Berkeley, where they conducted basic and applied research in the Department of Bioengineering. In 2017, they became a Board Observer at MICROBIOTICA LIMITED, representing the interests of the Wellcome Sanger Institute during the company's early stage growth phase on the Wellcome Genome Campus. In 2018, Ross was Market Development Lead at Repositive, where they helped researchers find, compare and share data from sources big and small. In 2019, they became a Consultant at Rounsevell Consulting, a Research Partnerships Lead at Sano Genetics, and a Board Observer and Head of Business Development at Bloc Labs. At Sano Genetics, Ross was responsible for a research platform that enables individuals to contribute to and participate in research into common and rare disease. At Bloc Labs, they were responsible for building analytics tools to support researchers in understanding proteins and their development towards therapeutic and industrial applications.

Ross Rounsevell completed a PhD in Biophysics at the University of Cambridge between 2001 and 2005. Ross then obtained a BSc(Hons) in Biochemistry at the University of Bath between 1996 and 2000. Prior to this, they completed an Art Foundation at Middlesex University between 1995 and 1996.